Table 4.
Age- and gender- adjusted vaccine effectiveness of 23-valent pneumococcal polysaccharide vaccine (PPV23) against invasive pneumococcal disease in people ≥60 in Germany. 95% CI shows the lower and upper bounds of the 95% confidence interval of the vaccine effectiveness estimate.
| All | vaccinated <2 years prior to IPD |
vaccinated between 2 and 4 years prior to IPD |
vaccinated ≥5 years prior to IPD |
Age 60–69 |
Age 70–79 |
Age ≥80 |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VE (%) | 95% CI (%) | VE (%) | 95% CI (%) | VE (%) | 95% CI (%) | VE (%) | 95% CI (%) | VE (%) | 95% CI (%) | VE (%) | 95% CI (%) | VE (%) | 95% CI (%) | |
| PPV23 serotypes | 37 | 12,55 | −29 | −159,31 | 56 | 17,76 | 40 | 4,63 | 43 | −820,100 | −5 | −538,83 | −17 | −80,77 |
| PPV23 serotypes except 3 | 63 | 49,74 | 45 | 4,69 | 69 | 41,85 | 66 | 44,79 | −252 | −520,77 | 8 | −373,37 | −3 | −335,48 |
| PPV23 serotypes except 3 and 8 | 58 | 40,70 | 51 | 12,74 | 52 | 9,76 | 62 | 36,78 | 62 | 21,83 | 59 | 28,78 | 51 | 16,72 |
| PPV23-nonPCV13 serotypes | 59 | 42,72 | 35 | −14,65 | 68 | 36,85 | 61 | 36,78 | 78 | 50,92 | 54 | 21,74 | 50 | 12,72 |
| Serotype 3 | −110 | −198,−47 | −178 | −393,−54 | −80 | −243,10 | −116 | −250,31 | 88 | −90,100 | 2 | −40,84 | 6 | −133,57 |